Proteolytic Shedding of CD46 from Human Hepatocytes Indicates Liver Stress

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Dec 19

PMID 39698100

Authors

Paul Kupke

Jordi Yang Zhou

Gunther Glehr

Paloma Riquelme

Lena Scheibert

Akinbami Adenugba

Hans J Schlitt

Edward K Geissler

Jens M Werner

James A Hutchinson

Affiliations

Soon will be listed here.

Abstract

Background: Routine liver function tests capture information about the metabolic and inflammatory condition of the liver, but we lack sensitive biomarkers of early hepatocyte stress. In humans, soluble CD46 (sCD46) levels in blood were recently identified as an accurate biomarker of hepatic steatosis. Here, we explore the diagnostic utility of sCD46 in other liver diseases.

Methods: We developed, optimised and validated an ELISA that facilitates measurements of human sCD46 in plasma, serum and culture supernatants. Then, we analysed mechanisms that lead to the release of sCD46 and identified its role in various hepatic stress conditions.

Results: We discovered that prostaglandin E2 (PGE2) drives upregulation of matrix metalloproteinase (MMP)-1 in fat-loaded hepatocytes, leading to proteolytic shedding of CD46. We further found that sCD46 release was increased by viral, toxic and hypoxic stresses.

Conclusions: sCD46 appears to be a promising biomarker with potential applications in the detection of early liver diseases or monitoring therapeutic responses, which could complement established diagnostic algorithms because sCD46 release is uniquely responsive to hepatocyte stress.

References

Bernal W, Wendon J . Acute liver failure. N Engl J Med. 2013; 369(26):2525-34. DOI: 10.1056/NEJMra1208937. View

Hansen A, Slater J, Biltoft M, Bundgaard B, Moller B, Hollsberg P . CD46 is a potent co-stimulatory receptor for expansion of human IFN-γ-producing CD8 T cells. Immunol Lett. 2018; 200:26-32. PMC: 7112827. DOI: 10.1016/j.imlet.2018.06.003. View

Gaggar A, Shayakhmetov D, Lieber A . CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003; 9(11):1408-12. DOI: 10.1038/nm952. View

Gloor Y, Schvartz D, Samer C . Old problem, new solutions: biomarker discovery for acetaminophen liver toxicity. Expert Opin Drug Metab Toxicol. 2019; 15(8):659-669. DOI: 10.1080/17425255.2019.1642323. View

Hoekstra L, de Graaf W, Nibourg G, Heger M, Bennink R, Stieger B . Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg. 2012; 257(1):27-36. DOI: 10.1097/SLA.0b013e31825d5d47. View

Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C . Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019; 25(12):1822-1832. PMC: 7147972. DOI: 10.1038/s41591-019-0675-0. View

Sanchez A, Feito M, Rojo J . CD46-mediated costimulation induces a Th1-biased response and enhances early TCR/CD3 signaling in human CD4+ T lymphocytes. Eur J Immunol. 2004; 34(9):2439-48. DOI: 10.1002/eji.200324259. View

Newsome P, Cramb R, Davison S, Dillon J, Foulerton M, Godfrey E . Guidelines on the management of abnormal liver blood tests. Gut. 2017; 67(1):6-19. PMC: 5754852. DOI: 10.1136/gutjnl-2017-314924. View

. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol. 2023; 79(2):461-491. DOI: 10.1016/j.jhep.2023.04.021. View

10.

Choileain S, Astier A . CD46 processing: a means of expression. Immunobiology. 2011; 217(2):169-75. PMC: 4363545. DOI: 10.1016/j.imbio.2011.06.003. View

11.

Giannini E, Testa R, Savarino V . Liver enzyme alteration: a guide for clinicians. CMAJ. 2005; 172(3):367-79. PMC: 545762. DOI: 10.1503/cmaj.1040752. View

12.

Kawano M, Seya T, Koni I, Mabuchi H . Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999; 116(3):542-6. PMC: 1905304. DOI: 10.1046/j.1365-2249.1999.00917.x. View

13.

Astier A, Meiffren G, Freeman S, Hafler D . Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest. 2006; 116(12):3252-7. PMC: 1635165. DOI: 10.1172/JCI29251. View

14.

Petrolati A, Festi D, DE BERARDINIS G, Colaiocco-Ferrante L, Di Paolo D, Tisone G . 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. Aliment Pharmacol Ther. 2003; 18(8):785-90. DOI: 10.1046/j.1365-2036.2003.01752.x. View

15.

Arbore G, West E, Rahman J, Le Friec G, Niyonzima N, Pirooznia M . Complement receptor CD46 co-stimulates optimal human CD8 T cell effector function via fatty acid metabolism. Nat Commun. 2018; 9(1):4186. PMC: 6180132. DOI: 10.1038/s41467-018-06706-z. View

16.

Andrade R, Chalasani N, Bjornsson E, Suzuki A, Kullak-Ublick G, Watkins P . Drug-induced liver injury. Nat Rev Dis Primers. 2019; 5(1):58. DOI: 10.1038/s41572-019-0105-0. View

17.

Trefts E, Gannon M, Wasserman D . The liver. Curr Biol. 2017; 27(21):R1147-R1151. PMC: 5897118. DOI: 10.1016/j.cub.2017.09.019. View

18.

Arroyo V, Moreau R, Jalan R . Acute-on-Chronic Liver Failure. N Engl J Med. 2020; 382(22):2137-2145. DOI: 10.1056/NEJMra1914900. View

19.

Santarpia L, Grandone I, Contaldo F, Pasanisi F . Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle. 2012; 4(1):31-9. PMC: 3581611. DOI: 10.1007/s13539-012-0083-5. View

20.

Fricker Z, Pedley A, Massaro J, Vasan R, Hoffmann U, Benjamin E . Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. Clin Gastroenterol Hepatol. 2018; 17(6):1157-1164.e4. PMC: 6475462. DOI: 10.1016/j.cgh.2018.11.037. View